Population Pharmacokinetic and Covariate Analysis of Apatinib, an Oral Tyrosine Kinase Inhibitor, in Healthy Volunteers and Patients with Solid Tumors.
about
Etirinotecan pegol administration is associated with lower incidences of neutropenia compared to irinotecan administration.Apatinib for metastatic breast cancer in non-clinical trial setting: Satisfying efficacy regardless of previous anti-angiogenic treatment.Pharmacokinetic Drug Interactions of Apatinib With Rifampin and Itraconazole.Apatinib combined with docetaxel as a salvage treatment for metastatic esophageal squamous cancer: a case report
P2860
Population Pharmacokinetic and Covariate Analysis of Apatinib, an Oral Tyrosine Kinase Inhibitor, in Healthy Volunteers and Patients with Solid Tumors.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Population Pharmacokinetic and ...... nd Patients with Solid Tumors.
@en
Population Pharmacokinetic and ...... nd Patients with Solid Tumors.
@nl
type
label
Population Pharmacokinetic and ...... nd Patients with Solid Tumors.
@en
Population Pharmacokinetic and ...... nd Patients with Solid Tumors.
@nl
prefLabel
Population Pharmacokinetic and ...... nd Patients with Solid Tumors.
@en
Population Pharmacokinetic and ...... nd Patients with Solid Tumors.
@nl
P2093
P2860
P1476
Population Pharmacokinetic and ...... nd Patients with Solid Tumors.
@en
P2093
Da-Fang Zhong
Lianshan Zhang
Mingming Yu
Xiaojian Dai
Xiaoyan Chen
Zhiwei Gao
P2860
P2888
P356
10.1007/S40262-016-0427-Y
P50
P577
2016-07-05T00:00:00Z